Oncopeptides AB (publ) (STO:ONCO)

Market Cap	625.74M -40.7%
Revenue (ttm)	83.24M +108.9%
Net Income	-221.10M
EPS	-0.91
Shares Out	395.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.583
Previous Close	1.583
Day's Range	1.551 - 1.628
52-Week Range	1.255 - 6.550
Beta	-1.33
Analysts	Hold
Price Target	2.50 (+59.24%)
Earnings Date	Aug 27, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 77
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ONCO stock is "Hold." The 12-month stock price target is kr 2.50, which is an increase of 59.24% from the latest price.

Price Target

kr 2.50

(59.24% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error